global consumer & retail conference - danone · every day, we swallow >1 bn bacteria 10...

38
Global Consumer & Retail Conference Pierre-André Terisse CFO New York, 18 November 2008

Upload: others

Post on 21-May-2020

3 views

Category:

Documents


0 download

TRANSCRIPT

Global Consumer & Retail Conference

Pierre-André TerisseCFO

New York, 18 November 2008

Treating malnutrition

Effects of

deshydratation on performances

Treating Immunity

infection & Allergies

Measuring stomach

distention

A Unique Mission

2

Danone has been successful and performing well over the past 10 years

1998 1999 2000 2001 2002 2003 2004 2005 2006 2007

* Like for like

CAGR(*): +6.9%

3

Danone has been successful and performing well over the past 10 years

1998 1999 2000 2001 2002 2003 2004 2004IFRS

2005 2006 2007

+40 bps annual margin progression for the last 10 years

4

Danone has been successful and performing well over the past 10 years

1998 1999 2000 2001 2002 2003 2004 2004IFRS

2005 2006 2007

EPS5

Health is more true than ever

Humans emerge from bacteria cells

Every day, we swallow >1 bn bacteria

10 times more bacteria inside us than human cells

It is estimated that the human body consists of 100,000 different bacteria

“During pregnancy and lactation period , 30 % go straight from mum's diet to baby development.”

A Unique Science to Consumer Model

Strong Blockbuster Brands Strong Blockbuster Brands

Health & ScienceHealth & Science

Geographical expansionGeographical expansion

1200 Danone Research employees50 clinical studies in 2008Danone as a center of a network of KOLsand stakeholders

Dairy: Activia, Actimel, Danonino, Vitalinea, DanacolWater: Evian, Bonafont, VolvicBaby: Aptamil, BebelacMedical: Neocate, Fortimel

700 million consumers every month7

DAIRY – outperforming the category

8

H1+ 7%

H1+ 10%

H1+ 28%

H1- 4%

Relative growth +5%

Mix +1.5%

Margin Dairy

Dairy Blockbusters Delta

2004 10.5% 21.3% 10.8%2005 7.0% 13.8% 6.8%2006 9.2% 16.1% 6.9%2007 12.2% 17.4% 5.2%

Average 9.7% 17.2% 7.4%

DAIRY – outperforming the category

9

Growth + 3%/+4%

+0.85% p.a.

2001 2002 2003 2004 2005 2006 2007

MS gain +0.85 pt

DAIRY – outperforming the category

10

Ukraine Ukraine –– 47 47 mlnmlnH1 H1 +41+41% % salessales

Chile Chile –– 1717 mlnmlnH1 H1 +24+24% % salessales

EgyptEgypt –– 74 74 mlnmlnH1 H1 +71+71% % salessales

ChinaChinaDairyDairy + + beveragesbeverages1.3 1.3 bnbn inhabitantsinhabitants

ThailandThailandDairyDairy65 65 mlnmln inhabitantsinhabitants

0

5

10

15

20

25

30

35

40

Netherl

ands

Turkey

Switzerl

and

S. Arab

iaDen

markBelg

iumCZ R

ep.

Sweden

Israe

lIre

land

Russia

Algeria

Japa

nAus

tralia

Greece

New Zea

land

Chile

Italy

Taiwan USA

Roman

iaHon

g Kon

gColo

mbiaVen

ezue

laMala

ysia

Vietna

mInd

ia

DAIRY – outperforming the category

0%

2%

4%

6%

8%

10%

12%

2001 2002 2003 2004 2005 2006 2007

Price/mix

Volume

3.3%

3.6% 4.0%

1.7%

1.3%

1.5%5.0%

DA

IRY

MT

EQU

ATI

ON

Market growth 5.7%Market share growth 3.5%

Sales growth 04-08 9.2%

Volume growth 6.2%Mix 1.5%Price 1.5%Sales growth 04-08 9.2%

Plain Still Water Market Value growth France

UK

Belgium

Spain

USA

Germany

Canada

Japan*

Poland

Turkey

Mexico

ArgentinaIndonesia

China South

WATERS – Two growth clusters: Industrialised Countries vs Emerging Countries

Source: Nielsen/Iri retail panel – InryoSoken for Japan12

WATERS – Two different environments:

Category vilifiedTap water is an alternativeEconomic slowdown

Category = Safety / healthBottled water & jugs are essentialLow per capita consumption

13

WATERS – Growth patterns and geographic mix develop accordingly

WA

TER

EQ

UA

TIO

N

EmergingDeveloped

USA

USA

2005 2008 H1

DEVELOPED EMERGING SALES

2005 1.1% 13.8% 5.8%2006 5.2% 11.4% 7.7%2007 0.2% 13.9% 6.2%

2008 YTD -5.5% 12.8% 3.0%

MT SALES 2.0% 10.0% 7.0%

All figures exclude WAHAHA sales

EmergingDeveloped

MARGINS

15

BABY – Setting the course for a healthy life

Growth & MetabolismBrain and Eye

Allergy Infection

Taste Development

Health

AllergyObesity

Coronary Heart DiseaseDiabetes

Birth + 36 months

Effectivity

- 9 months

16

BABY – The PCC opportunity remains huge across major markets

Source: Euromonitor for regional pcc and growth data; Nielsen data for France pcc

+ 6%

+ 11%

+ 3%

+ 11%

- 1%

+ 2%

+ 3%

CAGR 08-13WW average 32 kg/ pcc

France

Western Europe

North America

Eastern Europe

Latin America

APac

MEA

Per capita consumption (kg/ baby)

17

BABY – Providing a range for all ages, breaking barriers to consumption

Age in months

Inspired by mums:proximity with home-

made food

The reference:the largest and basic

daily range

The toddler plate:awakening, autonomy

Baby food share

of stomach

BABY – Accelerate the category

+4.4%+24.3%E- Europe

W-Europe

2004 2008 ytd

+7.7%+28.9%

+9.7%Asia +25.7%

Accelerating growth…

BABY DYNAMIC

Category +5.5%

Geo mix Asia & EECProduct mix MilkMarket shares

Danone + 10%

0%

10%

20%

30%

40%

50%

60%

France Italy UK Russia Poland Turkey Indonesia

2006 2007 2008 ytd

… based on mkt mix and MS growth

MEDICAL – Strong double-digit growth at high margins

.

HY 07* HY 08Q4 07 Q1 08 Q2 08 Q3 08

Sales growthSales growth EBIT Margin %EBIT Margin %

* Pro forma

MEDICAL – Increasing market sharesEurope & WW

20

2007 2008

WWEurope

Market growth +5.5% +8%

+ 0.9 pt

+ 1.1 pt

WW Europe

MEDICAL – Key elements for sustainable growth

Ageing population Strong organisation

External Internal

Product range

Innovation pipeline

R&D capability

Lifestyle diseases exploding

Increasing role of nutrition in disease management

Geographic expansion

Growing population

Medical – Product & geographical opportunities

+11.5%+14.5%E-Europe

W-Europe

2004 2008 ytd

+9.9%

- 7.0%AsiaDisease targetedMedical Nutrition

2008 YTD

More than 5% of sales Between 2% and 5% of sales Less than 2% of sales

Crisis as an opportunity

23

A more volatile financial environment

Major currencies / $

0.75

0.8

0.85

0.9

0.95

1

1.05

1.1

1.15

1.2

janv.-

08

janv.-

08

janv.-

08

févr.-08

févr.-08

mars-08

mars-08avr.

-08

avr.-08

mai-08

mai-08juin-

08juin-

08juil.-

08juil.-

08juil.-

08

août-

08

août-

08

sept.

-08

sept.

-08

oct.-0

8

oct.-0

8

EURUSD GBPUSD JPYUSD

Raising Default rates*

0.00%

2.00%

4.00%

6.00%

8.00%

10.00%

2007 2008 2009

0.7

0.75

0.8

0.85

0.9

0.95

1

1.05

1.1

1.15

1.2

janv.-08

janv.-08

janv.-08

févr.-08

févr.-08

mars-08

mars-08avr.

-08avr.

-08mai-0

8mai-0

8juin-08

juin-08juil.-

08juil.-

08juil.-

08

août-08

août-08

sept.-0

8

sept.-0

8oct.

-08oct.

-08

EURUSD BRLUSD RUBUSD

IDRUSD CNYUSD

Emerging Currencies / $

* Source : Moody ‘s

Mitigated by risk dispersion

1. Portfolio wellbalanced : emerging 43%western 57%

2. Only France andSpain exceed10% of portfolio

3. No other countryrepresents more than 7% sales

Asia Pacific 12%[0% - 5%]: Indonesia, China, Japan, Others

RoW%

Eastern Europe 15%

[5 % -10%]: Russia

[0% - 5%]: Poland, Turkey, Czech Republic, Others

Western Europe 48%>10%: France, Spain 

[5 % -10%]: UK & Ireland, Germany

[0% - 5%]: Benelux, Portugal & others

North America 9%[5 % -10%]: USA[0% - 5%]: Canada

Latin America 14%[5 % -10%]: Mexico

[0% - 5%]: Argentina, Brazil,Others

A sound financial structure

Financial Situation (as of 30.09.08)

Financial Net Debt €8.2 bn

Off-balance sheet commitments €2.7 bn

0

0.5

1

1.5

2

2.5

3

OTHERSCP * 2008 2009 2010 2011 2012 2013 2014 2015 2016 Put

(€ bn)

Bonds CP Others Put Options Syndicated Loans

The next big maturity is in December 2010 with the first tranche of the syndicated credit facility falling due

Our medium term financing is mainly already secured till Dec 2010 through syndicated facilities. EMTN & bonds issues.

µ Backed up by medium termcommitted credit facilities

More challenging economic conditions

GDP deceleration …

3.1%

2.6%

3.0%3.0%

4.7%

4.1%

2.6%

3.5%

4.0%

2.1%

4.1%

3.3%

4.0% 4.0%

3.2%

4.0%

Q1 04

Q2 04

Q3 04

Q4 04

Q1 05

Q2 05

Q3 05

Q4 05

Q1 06

Q2 06

Q3 06

Q4 06

Q1 07

Q2 07

Q3 07

Q4 07

-3% GDP growth on

Danone scope

Portfolio 2007 2008 08 vs 07 2009 09 vs 07

Western Europe 48% 2.6% 0.9% -1.7% -0.5% -3.1%Eastern Europe 15% 6.5% 5.6% -0.9% 2.8% -3.7%North America 9% 2.0% 1.3% -0.7% -0.7% -2.7%Latin America 14% 5.2% 3.8% -1.4% 1.7% -3.5%Asia 12% 8.8% 6.9% -1.9% 5.8% -3.0%Japan 2% 2.0% 0.4% -1.6% -0.4% -2.4%

WA Portfolio 4.2% 2.8% 1.0%-1.5% -3.2%

Source: JP Morgan Research

How does this impact our categories ?

10-12%

8-10%

5-10%

9-11%

MEDIUM TERM SHORT TERM

=

=

Dairy

Waters

Medical

8-10%

Quickly adapting our model to new market conditions

Reinnovation

Affordvaluization

Personnalisation & credibilization

Ubiquation

Leanization

29

Innovation

Premium price

TV 30 sec.

Modern trade & proximity

Complete Orga

Sept 08: €2 mln4th WW performance

Sept 08: €2.2 mln

Re-innovation: A new BB in Dairy

Danacol: Success in Russia & Argentina

Danacol: Success in Russia & Argentina

10,000

12,000

14,000

16,000

18,000

Sept 0

7Oct

07Nov 0

7Dec

07Ja

n 08Feb

08Mar

08Apr 0

8May

08Ju

ne 08

July

08Aug 08Sep

t 08

30

2009:Poland, CzechTurkey

2008/2009UK, Ireland, Spain,The Netherlands, Czech

Re-innovation Extending best success from Bledina & Numico

Roll out best innos Blédina/NumicoRoll out best innos Blédina/Numico

Meals 12 mnths + bols

FruitsDesserts

Soups

Cereals + Biscuits

31

Affordvaluization: Activia for CDE classes

Volume Evolution (Tons/Day)

Penetration increase speed in lower SEL

R$0.79 /100g R$0.79 / 100g R$1.00 / 100g

+ 51%No cannibalization

+ 51%No cannibalization

32 Source: Internal Data Source: Latin Panel

Aug06Sep

06Oct0

6Nov0

6Dec

06Ja

n07Feb

07Mar0

7Apr07May

07Ju

n07

Aug07Sep

07Oct0

7Nov0

7Dec

07jan

/08Feb

08Mar0

8Apr08May

08

Jun08

Jul07

Jan/04-

Dec/04

Jul/04-

Jun/05

Jan/05-

Dec/05

Jul/05-

Jun/06

Jan/06-

Dec/06

Jul/06-

Jun/07

Jan/07-

Dec/07

Jul/07-

Jun/08

2008 targets

+8% to +10%

EBIT margin* +40 bps to +50 bps

Underlying EPS growth** at least +15%

Sales growth FY 08*

* On a like-for-like basis

** versus pro forma

+5% to +6%][Sales growth Q4 08*

Target 2008

Medium-term guidance

EBIT margin* improving

Sales growth*

* On a like-for-like basis

Medium-term guidance

+8% to +10%

2009 guidance

* On a like-for-like basis

Sales growth*

2009 guidance

« A few points belowMedium-Term guidance »

Underlying EPS growth Double-digit growth

Continued improvementEBIT margin*

NOTES

NOTES

NOTES